

company announcement

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 19 January 2015 – On 30 October 2014, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 15.0 billion to be executed during a 12-month period beginning 30 January 2014.

Under the programme initiated 30 October 2014, Novo Nordisk will repurchase B shares for an amount up to DKK 3.8 billion in the period from 30 October 2014 to 28 January 2015.

Since the announcement as of 12 January 2015, the following transactions have been made under the programme:

	Number of B shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	10,833,000		2,901,986,132
12 January 2015	230,000	273.50	62,903,896
13 January 2015	200,000	277.78	55,556,180
14 January 2015	275,000	278.50	76,588,380
15 January 2015	215,000	279.83	60,163,343
16 January 2015	250,000	281.88	70,469,075
Accumulated under the programme	12,003,000		3,227,667,006

With the transactions stated above, Novo Nordisk owns a total of 59,487,153 B shares of DKK 0.20, corresponding to 2.2% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,650,000,000 including treasury shares.

Novo Nordisk A/S Investor Relations Novo Allé 2880 Bagsværd Denmark Telephone: +45 4444 8888 Novo Nordisk expects to repurchase B shares for an amount up to DKK 15.0 billion during a 12-month period beginning 30 January 2014. As of 16 January 2015, Novo Nordisk has repurchased a total of 57,026,995 B shares equal to a transaction value of DKK 14,432,042,221.

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 41,000 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit <u>novonordisk.com</u>, <u>Facebook</u>, <u>Twitter</u>, <u>LinkedIn</u>, <u>YouTube</u>

Further information

<i>Media:</i> Anne Margrethe Hauge	+45 3079 3450	amhg@novonordisk.com
Investors:		
Kasper Roseeuw Poulsen	+45 3079 4303	<u>krop@novonordisk.com</u>
Jannick Lindegaard Denholt	+45 3079 8519	<u>jlis@novonordisk.com</u>
Daniel Bohsen	+45 3079 6376	<u>dabo@novonordisk.com</u>
Melanie Raouzeos	+45 3075 3479	mrz@novonordisk.com
Frank Daniel Mersebach (US)	+1 609 235 8567	fdni@novonordisk.com

Novo Nordisk A/S Investor Relations Novo Allé 2880 Bagsværd Denmark Telephone: +45 4444 8888 Internet: www.novonordisk.com CVR no: 24 25 67 90

Company announcement No 3 / 2015